CN104284665B - 吡唑衍生物及其医药用途 - Google Patents

吡唑衍生物及其医药用途 Download PDF

Info

Publication number
CN104284665B
CN104284665B CN201380024202.3A CN201380024202A CN104284665B CN 104284665 B CN104284665 B CN 104284665B CN 201380024202 A CN201380024202 A CN 201380024202A CN 104284665 B CN104284665 B CN 104284665B
Authority
CN
China
Prior art keywords
constipation
compound
group
day
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380024202.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN104284665A (zh
Inventor
伊佐治正幸
竹村理明
伊泽英俊
布袋之彦
宫下格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kissei Pharmaceutical Co Ltd
Original Assignee
Kissei Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical Co Ltd filed Critical Kissei Pharmaceutical Co Ltd
Publication of CN104284665A publication Critical patent/CN104284665A/zh
Application granted granted Critical
Publication of CN104284665B publication Critical patent/CN104284665B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201380024202.3A 2012-05-07 2013-05-02 吡唑衍生物及其医药用途 Active CN104284665B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012105847 2012-05-07
JP2012-105847 2012-05-07
PCT/JP2013/062755 WO2013168671A1 (ja) 2012-05-07 2013-05-02 ピラゾール誘導体及びその医薬用途

Publications (2)

Publication Number Publication Date
CN104284665A CN104284665A (zh) 2015-01-14
CN104284665B true CN104284665B (zh) 2016-11-16

Family

ID=49550709

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380024202.3A Active CN104284665B (zh) 2012-05-07 2013-05-02 吡唑衍生物及其医药用途

Country Status (15)

Country Link
US (2) US9273085B2 (enExample)
EP (1) EP2848254B1 (enExample)
JP (2) JP5663699B2 (enExample)
KR (1) KR101868991B1 (enExample)
CN (1) CN104284665B (enExample)
AU (1) AU2013258566B2 (enExample)
BR (1) BR112014027841B1 (enExample)
CA (1) CA2872002C (enExample)
DK (1) DK2848254T3 (enExample)
ES (1) ES2601127T3 (enExample)
MX (1) MX359988B (enExample)
PL (1) PL2848254T3 (enExample)
PT (1) PT2848254T (enExample)
RU (1) RU2602739C2 (enExample)
WO (1) WO2013168671A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101890959B1 (ko) 2010-11-04 2018-08-22 알비레오 에이비 간질환 치료를 위한 ｉｂａｔ 억제제
PT2848254T (pt) * 2012-05-07 2016-10-05 Kissei Pharmaceutical Derivado de pirazol e utilização do mesmo para propósitos médicos
JP5807767B2 (ja) 2013-02-04 2015-11-10 大正製薬株式会社 便秘症の予防又は治療薬
CN106573033A (zh) * 2014-06-25 2017-04-19 Ea制药株式会社 固体制剂及其稳定化方法
CN106659726A (zh) 2014-06-25 2017-05-10 Ea制药株式会社 固体制剂及其着色防止或着色减少方法
BR112020019624A8 (pt) 2018-03-28 2022-03-03 Avolynt Método para tratar a hipoglicemia pós-prandial
CN112449637B (zh) 2018-06-05 2024-03-19 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
SG11202012151XA (en) 2018-06-20 2021-01-28 Albireo Ab Crystal modifications of odevixibat
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
MX2021008981A (es) 2019-02-06 2021-09-08 Albireo Ab Compuestos de benzotiadiazepina y su uso como moduladores del acido biliar.
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
JP7696898B2 (ja) 2019-12-04 2025-06-23 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
CA3158184A1 (en) 2019-12-04 2021-08-10 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
CN114761080B (zh) 2019-12-04 2024-07-23 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
EP4069360B1 (en) 2019-12-04 2024-01-03 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
ES3002777T3 (en) 2020-08-03 2025-03-07 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
EP4243831A1 (en) 2020-11-12 2023-09-20 Albireo AB Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
EP4255565A1 (en) 2020-12-04 2023-10-11 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009084531A1 (ja) * 2007-12-27 2009-07-09 Kissei Pharmaceutical Co., Ltd. ピラゾール誘導体のモノセバシン酸塩
WO2011002001A1 (ja) * 2009-07-01 2011-01-06 キッセイ薬品工業株式会社 ピラゾール誘導体とビグアナイド薬との組み合わせ医薬

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004137245A (ja) 2002-08-23 2004-05-13 Kissei Pharmaceut Co Ltd ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
MX2008013583A (es) * 2006-04-26 2008-10-31 Genentech Inc Compuestos del inhibidor de fosfoinositido 3-cinasa y composiciones farmaceuticas que los contienen.
EP2275430B1 (en) * 2008-04-16 2012-05-16 Kissei Pharmaceutical Co., Ltd. Hemifumarate of a pyrazole derivative
AR087701A1 (es) 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
PT2848254T (pt) * 2012-05-07 2016-10-05 Kissei Pharmaceutical Derivado de pirazol e utilização do mesmo para propósitos médicos

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009084531A1 (ja) * 2007-12-27 2009-07-09 Kissei Pharmaceutical Co., Ltd. ピラゾール誘導体のモノセバシン酸塩
WO2011002001A1 (ja) * 2009-07-01 2011-01-06 キッセイ薬品工業株式会社 ピラゾール誘導体とビグアナイド薬との組み合わせ医薬

Also Published As

Publication number Publication date
DK2848254T3 (en) 2016-10-31
HK1204773A1 (en) 2015-12-04
KR101868991B1 (ko) 2018-06-19
CN104284665A (zh) 2015-01-14
US9273085B2 (en) 2016-03-01
RU2014149181A (ru) 2016-06-27
PT2848254T (pt) 2016-10-05
BR112014027841B1 (pt) 2022-08-09
JPWO2013168671A1 (ja) 2016-01-07
CA2872002C (en) 2019-01-15
BR112014027841A8 (pt) 2021-09-28
RU2602739C2 (ru) 2016-11-20
JP5663699B2 (ja) 2015-02-04
WO2013168671A1 (ja) 2013-11-14
KR20150013671A (ko) 2015-02-05
JP2015083580A (ja) 2015-04-30
EP2848254A4 (en) 2015-07-15
US20150141631A1 (en) 2015-05-21
MX2014013696A (es) 2015-02-05
EP2848254B1 (en) 2016-08-03
CA2872002A1 (en) 2013-11-14
US20160129031A1 (en) 2016-05-12
PL2848254T3 (pl) 2017-03-31
AU2013258566B2 (en) 2017-03-16
MX359988B (es) 2018-10-18
US9694027B2 (en) 2017-07-04
EP2848254A1 (en) 2015-03-18
JP6105546B2 (ja) 2017-03-29
ES2601127T3 (es) 2017-02-14
AU2013258566A1 (en) 2014-11-27
BR112014027841A2 (pt) 2017-06-27

Similar Documents

Publication Publication Date Title
CN104284665B (zh) 吡唑衍生物及其医药用途
JP7312169B2 (ja) 遺伝性てんかん性障害の処置に使用するガナキソロン
CN103338768A (zh) 胃和结肠的配制剂及其制备和使用方法
JP2011157372A (ja) 機能性腸障害を処置する方法
JP6473254B2 (ja) 下痢を治療するための製品及び方法
UA122974C2 (uk) Комбінований лікарський засіб, який містить канагліфлозин і фентермін, для лікування ожиріння й пов'язаних з ожирінням порушень
KR20200017487A (ko) 비알코올성 지방간염 치료를 위한 리코플리고진
JP2003525865A (ja) 非定型抗精神病薬の投与による神経性過食症および関連摂食障害の治療方法
HK1204773B (en) Pyrazole derivative and use thereof for medical purposes
US20200038413A1 (en) Methods of treating parkinson's disease using aminosterol compositions
Eldalal et al. The Correlation between Pharmacological Param-eters of Oxycodone and Opioid Epidemic
CN110101696B (zh) 一种氨来呫诺在利尿上的制药用途
US20200038414A1 (en) Methods of treating constipation using aminosterol compositions
US20220265785A1 (en) Composition for preventing or treating uric acid-related disease

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1204773

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1204773

Country of ref document: HK